Showing results (161-170 of 169) with videos related to
Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 169 results.
Bioorganic & Medicinal Chemistry Letters|August 19, 2008
Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2Bruce A Ellsworth, Wei Meng, Manorama Patel, et al.Clinical Genetics|December 23, 2016
Genetic heterogeneity in Pakistani microcephaly families revisitedI Ahmad, S M Baig, A R Abdulkareem, et al.Journal of Medicinal Chemistry|June 22, 2017
Utilization of an Active Site Mutant Receptor for the Identification of Potent and Selective Atypical 5-HT2C Receptor AgonistsJoseph Carpenter, Ying Wang, Gang Wu, et al.Bioorganic & Medicinal Chemistry Letters|May 30, 2007
Arylpropanolamines: selective beta3 agonists arising from strategies to mitigate phase I metabolic transformationsW N Washburn, T W Harper, G Wu, et al.Journal of Medicinal Chemistry|February 12, 2008
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetesWei Meng, Bruce A Ellsworth, Alexandra A Nirschl, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2001
BMS-196085: a potent and selective full agonist of the human beta(3) adrenergic receptorA V Gavai, P M Sher, A B Mikkilineni, et al.Bioorganic & Medicinal Chemistry Letters|June 5, 2004
BMS-201620: a selective beta 3 agonistW N Washburn, C-Q Sun, G Bisacchi, et al.Journal of Medicinal Chemistry|November 5, 2013
Reductions in log P improved protein binding and clearance predictions enabling the prospective design of cannabinoid receptor (CB1) antagonists with desired pharmacokinetic propertiesBruce A Ellsworth, Philip M Sher, Ximao Wu, et al.Bioorganic & Medicinal Chemistry Letters|November 21, 2001
Beta 3 agonists. Part 1: evolution from inception to BMS-194449W N Washburn, P M Sher, K M Poss, et al.Pageof 17